BioSpace News Archive

A recap of where life sciences cash has been flowing the past week.

Although Gamestop dominated the financial news this week, surging more than 1,600% in January, Novavax actually saw greater growth in 2020, with year-to-year gains of 2,731% that exceeded those of all the coronavirus stocks.

The next several years will be transformative in the cell and gene therapy space, and Immatics’ Chief Medical Officer Cedrik M. Britten believes his company’s engineered T-cell receptors may play an important role in providing treatment options for cancer patients.

- Company secures next step to continue to build-out pipeline of assets - University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it will host a live webinar for the investment community on Tuesday, February 16, 2021 at 1:00 p.m. EST to review clinical data on the company’s investigational AAV-based gene therapies ABO-102 and ABO-101 presented at the 17 th Annual WORLD Symposium ™.

J.R. Rahn to become sole CEO; Perry Dellelce to become Chair; Stephen Hurst retires as executive but remains on board; Stanley Glick retires as board member.

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that Chief Executive Officer Scott Hutton was selected as the CEO of the Year, 2020

THREAD, an innovative technology and service provider that enables decentralized clinical trials (DCTs), and 1nHealth, a digital technology company that works with study sponsors to optimize patient recruitment, today announced a new strategic partnership to enhance recruitment and retention outcomes in DCTs.

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop a next-generation AI- and machine learning-powered software for its PURE EP

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke.